R
Radj Gervais
Researcher at University of Caen Lower Normandy
Publications - 177
Citations - 16277
Radj Gervais is an academic researcher from University of Caen Lower Normandy. The author has contributed to research in topics: Lung cancer & non-small cell lung cancer (NSCLC). The author has an hindex of 38, co-authored 160 publications receiving 14412 citations. Previous affiliations of Radj Gervais include University of California, San Francisco & Pennsylvania Hospital.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Nasser H. Hanna,Frances A. Shepherd,Frank V. Fossella,José Rodrigues Pereira,Filippo de Marinis,Joachim von Pawel,Ulrich Gatzemeier,Thomas Chang Yao Tsao,Miklos Pless,Thomas Müller,Hong-Liang Lim,Christopher Desch,Klara Szondy,Radj Gervais,Shaharyar,Christian Manegold,Sofia Paul,Paolo Paoletti,Lawrence H. Einhorn,Paul A. Bunn +19 more
TL;DR: Treatment with pemetrexed resulted in clinically equivalent efficacy outcomes, but with significantly fewer side effects compared with docetaxel in the second-line treatment of patients with advanced NSCLC and should be considered a standard treatment option for second-liners when available.
Journal ArticleDOI
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman,Igor Puzanov,Vivek Subbiah,Jason E. Faris,Ian Chau,Jean-Yves Blay,Juergen Wolf,Noopur Raje,Eli L. Diamond,Antoine Hollebecque,Radj Gervais,Maria Elena Elez-Fernandez,Antoine Italiano,Ralf-Dieter Hofheinz,Manuel Hidalgo,Emily Chan,Martin Schuler,Susan Frances Lasserre,Martina Makrutzki,Florin Sirzen,Maria Luisa Veronese,Josep Tabernero,José Baselga +22 more
TL;DR: BRAF V600 appears to be a targetable oncogene in some, but not all, nonmelanoma cancers and preliminary vemurafenib activity was observed in non-small-cell lung cancer and in Erdheim-Chester disease and Langerhans'-cell histiocytosis.
Journal ArticleDOI
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Edward S. Kim,Vera Hirsh,Tony Mok,Mark A. Socinski,Radj Gervais,Yi-Long Wu,Long Yun Li,Claire Watkins,Mark V. Sellers,Elizabeth S. Lowe,Yan Sun,Mei Lin Liao,Kell Østerlind,Martin Reck,Alison Armour,Frances A. Shepherd,Scott M. Lippman,Jean-Yves Douillard +17 more
TL;DR: Non-inferior survival of gefitinib compared with docetaxel is established, suggesting that gef itinib is a valid treatment for pretreated patients with advanced non-small-cell lung cancer.
Journal ArticleDOI
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Gérard Zalcman,Gérard Zalcman,Julien Mazieres,Jacques Margery,Laurent Greillier,Clarisse Audigier-Valette,Denis Moro-Sibilot,Olivier Molinier,Romain Corre,Isabelle Monnet,Valérie Gounant,Frédéric Rivière,H. Janicot,Radj Gervais,Chrystele Locher,Bernard Milleron,Quan Tran,Marie-Paule Lebitasy,Franck Morin,Christian Creveuil,Jean-Jacques Parienti,Arnaud Scherpereel +21 more
TL;DR: Addition of bevacizumab to pemetrexed plus cisplatin significantly improved OS in malignant pleural mesothelioma at the cost of expected manageable toxic effects, therefore it should be considered as a suitable treatment for the disease.